BMS-986263 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BMS-986263’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BMS-986263 (ND-L02-s0201) is under development for the treatment of non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis and cirrhosis secondary to non-alcoholic steatohepatitis (NASH) and hepatitis C. The drug candidate is administered through intravenous route. It is a vitamin A-coupled lipid nanoparticle (LNP) containing siRNA against heat shock protein 47 (HSP47). The drug candidate is based on siRNA technology.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of BMS-986263’s drug-specific PTSR and LoA scores, buy the report here.